

**TEST CHANGE**

**Drug Panel 9A, Urine - Screen with Reflex to Confirmation/Quantitation**

0092187, CDASU 9A

**Specimen Requirements:**

**Patient Preparation:**

**Collect:** Random urine.

**Specimen Preparation:** Transfer 8 mL urine with no additives or preservatives in ARUP Standard Transport Tubes. (Min: 4 mL)

**Transport Temperature:** Refrigerated.

**Unacceptable Conditions:** Specimens exposed to repeated freeze/thaw cycles.

**Remarks:**

**Stability:** Ambient: 1 week; Refrigerated: 1 month; Frozen: 1 month

**Methodology:** Enzyme Immunoassay/Gas Chromatography-Flame Ionization Detection/Gas Chromatography-Mass Spectrometry/Liquid Chromatography-Tandem Mass Spectrometry

**Performed:** Sun-Sat

**Reported:** 1-4 days

**Note:** If the specimen screens positive, then Confirmation/Quantitation by GC/MS, GC/FID, and/or LC-MS/MS will be added to confirm result. Additional charges apply. To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).

**CPT Codes:** 80307; if reflexed, add 80320; 80325; 80345; 80346; 80349; 80353; 80358; 80359; 80361; 80365; 80367; 83992 (Reflexed Alt Code: G0480)

**New York DOH Approval Status:** This test is New York DOH approved.

**Interpretive Data:**

The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS, GC/FID, and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Oxycodone results are reported with the opiates results. MDMA results are reported with the amphetamines results. The following opioids are not detected in this test: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.

**Reference Interval:**

[Effective August 17, 2015](#)

Drugs Covered and Cutoff Concentrations	
Drugs/Drug Classes	Screen
THC (Cannabinoids)	5020 ng/mL
Cocaine	150 ng/mL
Opiates	300 ng/mL
Oxycodone	100 ng/mL
Phencyclidine	25 ng/mL
Amphetamines	300 ng/mL
MDMA (Ecstasy)	500 ng/mL
Barbiturates	200 ng/mL
Benzodiazepines	200 ng/mL
Methadone	150 ng/mL
Propoxyphene	300 ng/mL
Alcohol	40 mg/dL